2228 related articles for article (PubMed ID: 22041508)
1. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
3. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
4. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
Zarakolu P; Hasçelik G; Unal S
Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
7. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
8. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
[TBL] [Abstract][Full Text] [Related]
11. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).
Flamm RK; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):233-8. PubMed ID: 25128477
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
Sader HS; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
[TBL] [Abstract][Full Text] [Related]
16. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
17. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
[TBL] [Abstract][Full Text] [Related]
19. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
[TBL] [Abstract][Full Text] [Related]
20. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
